Trial Profile

A Phase Ib/II Study of AK112 PD-1/VEGF Bispecific Antibody in Combination With AK117 Anti-CD47 Antibody in Advanced Malignant Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ivonescimab (Primary) ; Ligufalimab (Primary) ; Carboplatin; Cisplatin; Fluorouracil
Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Oropharyngeal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors Akeso Biopharma

Most Recent Events

16 Sep 2024 According to Akeso Biopharma media release, the company presented the data from the study at the 2024 European Society for Medical Oncology Annual Meeting (ESMO 2024) in Barcelona, Spain.
16 Sep 2024 Results published in the Media Release
15 Sep 2024 Results presented in an Akeso media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com